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Abstract. MedCo is the first operational system that makes sensitive medical-data 
available for research in a simple, privacy-conscious and secure way. It enables a 
consortium of clinical sites to collectively protect their data and to securely share 
them with investigators, without single points of failure. In this short paper, we 
report on our ongoing effort for the operational deployment of MedCo within the 
context of the Swiss Personalized Health Network (SPHN) for the Swiss Molecular 
Tumor Board. 
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1.Introduction 
Although within Swiss Personalized Health Network much effort is currently being put 
into data interoperability and integration, data privacy and security represent important 
challenges that, if overlooked, can potentially hinder or even block the access and use of 
this data across the different hospitals. To tackle these issues, researchers from the Swiss 
Personalized Oncology project and the Data Protection for Personalized Health (DPPH 
https://dpph.ch) project have joined forces. The intention is to work together towards the 
development and the adoption of cutting-edge privacy-preserving solutions for data 
analytics that provide strong and long-lasting protection guarantees for patient data. 
2.The Swiss Molecular Tumor Board Use Case 
As a first step in this direction, the idea is to empower the Swiss Molecular Tumor Board 
(SMTB), which is meant to be a reference for the entire country for analysing complex 
cases and identifying the best personalized treatment, with MedCo, the first privacy-
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preserving tool issued by the DPPH project that is co-developed by EPFL and the 
Lausanne University Hospital (https://medco.epfl.ch). MedCo [1] is a data discovery 
system that enables a researcher or clinician to securely perform, through a user-friendly 
graphical interface, exploratory queries (SQL-like queries for simple statistics) on 
encrypted clinical and molecular data that are horizontally partitioned across different 
hospitals. By relying on state-of-the-art technologies for information security such as 
homomorphic encryption, secure multi-party computation and differential privacy, 
MedCo ensures (1) that patients’ individual-level data are protected against illegitimate 
access by unauthorized people, (2) that no single authority has to be trusted for the 
security of the data and (3) that the re-identification risk is minimized. 
 Our goal is to deploy MedCo at all the University Hospitals in order to enable 
the SMTB to make more informed treatment decisions (Figure 1). MedCo will offer 
experts of the SMTB the possibility of obtaining, in real time, simple statistics and 
aggregate information about treatment and outcome for patients with a similar clinical 
and molecular profile to the ones under evaluation (e.g. overall survival, overall response 
rate, progression-free survival). At the same time, the use of MedCo will ensure that the 
privacy of both the patients in the hospitals and the patient presented at the SMTB is 
preserved. To securely identify similar patients, MedCo will perform an encrypted search 
over all the oncology patients whose data is stored encrypted in the MedCo databases 
that are distributed across the five Swiss University Hospitals and then compute the 
requested aggregate information directly on the encrypted data of the identified patients. 
 
 
 
Figure 1. Envisioned use of MedCo in the Swiss Molecular Tumor Board. DCC: Data Coordination Center 
3.Conclusion
MedCo will be initially deployed in the University Hospitals of Bern, Geneva and 
Lausanne for testing purposes. Once the data loading process, the governance and the 
functionalities of MedCo will be validated by the SPHN Data Coordination Center, the 
deployment will be extended to the University Hospitals of Basel and Zurich and the 
other hospitals members of the Swiss Group for Clinical Cancer Research , eventually. 
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